Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on CERULEAN PHARMA INC. We currently have 6 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
CERULEAN PHARMA INC
CERULEAN PHARMA INC
Update on ovarian cancer and CRLX301
24 Jun 16
Cerulean recently presented the results on the Phase Ib trial of CRLX101 with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer. The nine-patient trial showed a 56% overall response rate (ORR). The company also reported data from the Phase I/IIa dose escalation trial of CRLX301 (docetaxel nanoparticle conjugate) for solid tumors. The primary purpose of the study was to determine the maximum tolerated dose, but six of the 13 patients evaluable for efficacy were stabilized during the study.
Phase II renal data pushed to Q3 from Q2
17 May 16
Cerulean reported first quarter results and provided a pipeline update on 2 May, while confirming an expected cash runway for the company into 2017. Management has pushed back its timing for an announcement on the highly awaited top-line data for CRLX101 in renal cancer. Critical Phase II top-line data in RCC are now expected in Q316 (changed from end-June), due to an apparent slowing of the rate of disease progression in patients.
Approaching release of Phase II renal data
16 Mar 16
2015 results, reiterating an expected cash runway into 2017 and confirming timelines for releasing clinical data for key pipeline projects in H116 are on track. Phase II data in renal cancer are expected by end June for its highprofile CRLX101, which uses its nanoparticle drug delivery system
Collaborating with big pharma
19 Nov 15
Cerulean reported in-line Q3 results on 16 November followed by an investor call highlighting its growing clinical program for treatments using its unique nanoparticle drug conjugation NDC delivery system. If successful, lead compound CRLX101 will launch as a new mechanism of action in third- and fourth-line renal cell cancer where there are few treatment options. Its technology holds the potential for numerous NDC combinations with currently marketed drugs, underlined by its newly announced collaboration with AstraZeneca.
Multiple price inflections on clinical pipeline
10 Sep 15
Cerulean is on track to announce critical Phase II trial results for CRLX101 in metastatic renal cancer (mRCC) in H116 following encouraging preliminary efficacy data in a Phase IIa readout presented at ASCO in 2015. Additionally, interim Phase Ib/II results are due for CRLX101 in ovarian and rectal cancers in H215 and Phase I data for CRLX301 in 2015 in solid tumors. If positive, these results should renew confidence in Cerulean’s pipeline and its differentiated nanoparticle drug conjugate technology (NDC). We value Cerulean at $273m ($10.0 per share).
Multiple data readouts in coming quarters
10 Aug 15
In its Q2 results on 6 August, Cerulean confirmed its clinical programme is progressing to plan and continues to expect numerous critical data readouts over the next 12 months. Most notably, results from its Phase II trial of CRLX101 in renal cell cancer (RCC) will be announced in Q216 while initial clinical data for CRLX301 are expected in Q4 of this year. We highlight that recent announcements by two peers progressing first- and second-line treatments for RCC could bode well for CRLX101 as a leading contender in the third- and fourth-line RCC setting in this indication.
19 Jan 17
Aggregated Micro Power* (AMPH): Funding for first peaking power plant project (CORP) | The Mission Marketing Group* (TMMG): Positive trading update (CORP) | Cello (CLL): Increasingly backed by, and leveraging, technology (BUY) | 4imprint (FOUR): Growth backed by strong cash flow continues (BUY) | Allergy Therapeutics (AGY): Positive trading update and market share gains drive upgrades (BUY) | Shanta Gold (SHG): Q4 operating results (BUY) | Sound Energy (SOU): Tendrara extended well test result (BUY) | Revolution Bars (RBG): Price target increase (BUY)
N+1 Singer - Northern lights - Shining prospects for 2017
16 Jan 17
As the birthplace of Stephenson, Armstrong and Swan, the North East of England has a proud history of industrial and technological innovation. Despite local economic challenges, the region’s industrial heritage lives on through continuing success in high end engineering and technology. The recent takeovers of private equity backed SMD (subsea robotics) and Nomad Digital (wi-fi on the railways) are testament to this. The North East has also emerged as a leader in genetics and genomics with an enviable life sciences and healthcare infrastructure. Against this backdrop, we expect the region to continue to throw up attractive IPO candidates to build on the six new listings in the past three years. We expect 2017 to be far kinder to the existing portfolio of North East plcs than 2016 (a year to forget) with recent management changes one important theme for the new year. Our top picks are Hargreaves Services, Quantum Pharma and Zytronic (all N+1 Singer Corporate clients) and we are Buyers of Northgate and Grainger.
N+1 Singer - Morning Song 16-01-2017
16 Jan 17
APPLIED GRAPHENE MATERIALS PLC (AGM LN) | BELLWAY (BWY LN) | GOALS SOCCER CENTRES (GOAL LN) | GRAFENIA PLC (GRA LN) | GRAINGER PLC (GRI LN) | GREGGS (GRG LN) | HARGREAVES SERVICES (HSP LN) | IMMUNODIAGNOSTIC SYSTEMS HLDGS (IDH LN) | INSTEM PLC (INS LN) | KROMEK GROUP PLC (KMK LN) | NORTHGATE PLC (NTG LN) | QUANTUM PHARMA PLC (QP/ LN) | RHYTHMONE PLC (RTHM LN) | SCS GROUP PLC (SCS LN) | SHIELD THERAPEUTICS PLC (STX LN) | SQS SOFTWARE QUALITY SYSTEMS AG (SQS LN) | UTILITYWISE PLC (UTW LN) | VERTU MOTORS PLC (VTU LN) | VISLINK PLC (VLK LN) | ZYTRONIC (ZYT LN)
N+1 Singer - Morning Song 19-01-2017
19 Jan 17
ACTUAL EXPERIENCE PLC (ACT LN) | BAGIR GRP LTD (BAGR LN) | BIOQUELL (BQE LN) | BROWN(N.)GROUP (BWNG LN) | CARADOR INCOME FUND PLC (CIFU LN) | HALFORDS GROUP (HFD LN) | NCC GROUP (NCC LN) | ST IVES PLC (SIV LN) | SUMMIT THERAPEUTICS PLC (SUMM LN) | WILMINGTON PLC (WIL LN)
Small Cap Breakfast
17 Jan 17
Global Energy Development (GED.L) — To be renamed Nautilus Marine Services. Schedule 1 from developer and seller of hydrocarbons and related products. Reverse takeover. Raising $10.5m via a convertible. Expected 9 Feb. Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.
N+1 Singer - Best Ideas 2017 - Top picks
04 Jan 17
Today we publish our Best Ideas for 2017 - 12 stocks that we believe have excellent prospects in the current year together with a detailed discussion of what we see as the key sector and market themes for 2017. Our top picks are Cineworld, Elementis, Herald Investment Trust, Hill & Smith, IQE, MySale, Redde, ReNeuron, RhythmOne, SDL, Servelec and Severfield.